CONTEXT: Expression of the vasoconstrictor and proinflammatory peptide endothelin (ET)-1 is increased in insulin-resistant (IR) subjects. OBJECTIVE: The aim of this study was to investigate whether ET-1 regulates skeletal muscle glucose uptake in IR subjects in vivo and in cultured human skeletal muscle cells. DESIGN AND PARTICIPANTS: Eleven subjects participated in three protocols using brachial artery infusion of: A) BQ123 (10 nmol/min) and BQ788 (10 nmol/min) (ET(A) and ET(B) receptor antagonist, respectively), followed by coinfusion with insulin (0.05 mU/kg/min); B) insulin alone; and C) insulin followed by coinfusion with ET-1 (20 pmol/min). MAIN OUTCOME MEASURES: Forearm blood flow (FBF) and forearm glucose uptake (FGU) were determined. Glucose uptake and molecular signaling were determined in cultured skeletal muscle cells. RESULTS: ET(A)/ET(B) receptor blockade increased FGU by 63% (P < 0.05). Coadministration of insulin caused a further 2-fold increase in FGU (P < 0.001). ET(A)/ET(B) receptor blockade combined with insulin resulted in greater FGU than insulin infusion alone (P < 0.005). ET(A)/ET(B) receptor blockade increased FBF by 30% (P < 0.05), with a further 16% increase (P < 0.01) during insulin coinfusion. ET-1 decreased basal FBF by 35% without affecting FGU. ET-1 impaired basal and insulin-stimulated glucose uptake in cultured muscle cells (P < 0.01) via an effect that was prevented by ET(A)/ET(B) receptor blockade. CONCLUSION: ET(A)/ET(B) receptor blockade enhances basal and insulin-stimulated glucose uptake in IR subjects. ET-1 directly impairs glucose uptake in skeletal muscle cells via a receptor-dependent mechanism. These data suggest that ET-1 regulates glucose metabolism via receptor-dependent mechanisms in IR subjects.
CONTEXT: Expression of the vasoconstrictor and proinflammatory peptide endothelin (ET)-1 is increased in insulin-resistant (IR) subjects. OBJECTIVE: The aim of this study was to investigate whether ET-1 regulates skeletal muscle glucose uptake in IR subjects in vivo and in cultured human skeletal muscle cells. DESIGN AND PARTICIPANTS: Eleven subjects participated in three protocols using brachial artery infusion of: A) BQ123 (10 nmol/min) and BQ788 (10 nmol/min) (ET(A) and ET(B) receptor antagonist, respectively), followed by coinfusion with insulin (0.05 mU/kg/min); B) insulin alone; and C) insulin followed by coinfusion with ET-1 (20 pmol/min). MAIN OUTCOME MEASURES: Forearm blood flow (FBF) and forearm glucose uptake (FGU) were determined. Glucose uptake and molecular signaling were determined in cultured skeletal muscle cells. RESULTS: ET(A)/ET(B) receptor blockade increased FGU by 63% (P < 0.05). Coadministration of insulin caused a further 2-fold increase in FGU (P < 0.001). ET(A)/ET(B) receptor blockade combined with insulin resulted in greater FGU than insulin infusion alone (P < 0.005). ET(A)/ET(B) receptor blockade increased FBF by 30% (P < 0.05), with a further 16% increase (P < 0.01) during insulin coinfusion. ET-1decreased basal FBF by 35% without affecting FGU. ET-1 impaired basal and insulin-stimulated glucose uptake in cultured muscle cells (P < 0.01) via an effect that was prevented by ET(A)/ET(B) receptor blockade. CONCLUSION: ET(A)/ET(B) receptor blockade enhances basal and insulin-stimulated glucose uptake in IR subjects. ET-1 directly impairs glucose uptake in skeletal muscle cells via a receptor-dependent mechanism. These data suggest that ET-1 regulates glucose metabolism via receptor-dependent mechanisms in IR subjects.
Authors: Lauren K Park; Elizabeth J Parks; Ryan J Pettit-Mee; Makenzie L Woodford; Thaysa Ghiarone; James A Smith; Allan R K Sales; Luis A Martinez-Lemus; Camila Manrique-Acevedo; Jaume Padilla Journal: J Appl Physiol (1985) Date: 2020-07-02
Authors: Lauren K Walsh; Thaysa Ghiarone; T Dylan Olver; Areli Medina-Hernandez; Jenna C Edwards; Pamela K Thorne; Craig A Emter; Jonathan R Lindner; Camila Manrique-Acevedo; Luis A Martinez-Lemus; Jaume Padilla Journal: J Physiol Date: 2018-11-24 Impact factor: 5.182
Authors: Leryn J Reynolds; Daniel P Credeur; Camila Manrique; Jaume Padilla; Paul J Fadel; John P Thyfault Journal: J Appl Physiol (1985) Date: 2016-10-27
Authors: Thomas J Jurrissen; Zachary I Grunewald; Makenzie L Woodford; Nathan C Winn; James R Ball; Thomas N Smith; Andrew A Wheeler; Arthur L Rawlings; Kevin F Staveley-O'Carroll; Yan Ji; William P Fay; Pierre Paradis; Ernesto L Schiffrin; Victoria J Vieira-Potter; Paul J Fadel; Luis A Martinez-Lemus; Jaume Padilla Journal: Am J Physiol Endocrinol Metab Date: 2019-07-16 Impact factor: 4.310
Authors: Benjamin E Young; Jaume Padilla; Stine H Finsen; Paul J Fadel; Stefan P Mortensen Journal: Endocrinology Date: 2022-03-01 Impact factor: 4.736
Authors: Alexey Shemyakin; Firoozeh Salehzadeh; Daniella Esteves Duque-Guimaraes; Felix Böhm; Eric Rullman; Thomas Gustafsson; John Pernow; Anna Krook Journal: Diabetes Date: 2011-06-15 Impact factor: 9.461